TIMOTHY B ECKEL

Allopathic & Osteopathic Physicians|Family Medicine DANVILLE, PA NPI 1821085572

General Payments — all program years on this page

$672.99

  • Category: General Payments
  • Program years: PY2018–2019
  • Record count: 51
  • As of (CMS publication): 2026-01-23

Latest program year (PY2019): $292.04 across 22 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2019) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $259.7721
Education $32.271

By paying entity

Latest program year (PY2019) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $380.9529
2019 $292.0422

Records — PY2019 (22)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
658199499 Lilly USA, LLC $14.73 06/20/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
659183323 Novartis Pharmaceuticals Corporation $15.16 06/13/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
659183327 Novartis Pharmaceuticals Corporation $12.98 03/07/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
668745353 Novo Nordisk Inc $11.61 01/10/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
668745355 Novo Nordisk Inc $13.92 01/17/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
668745357 Novo Nordisk Inc $13.93 02/19/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
669461871 Novo Nordisk Inc $10.48 03/12/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
669556669 Novo Nordisk Inc $16.30 04/04/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
669556671 Novo Nordisk Inc $15.34 04/09/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
669601661 Novo Nordisk Inc $14.03 05/23/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
670285423 Allergan Inc. $13.77 02/28/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
673047275 PFIZER INC. $15.31 03/21/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
673062878 PFIZER INC. $13.94 05/14/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
674433131 Novo Nordisk Inc $14.35 06/11/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
674475037 Novo Nordisk Inc $16.64 07/18/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
674475039 Novo Nordisk Inc $12.44 07/11/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
682676249 Novo Nordisk Inc $4.81 04/02/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
682676259 Novo Nordisk Inc $2.85 06/25/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
682676261 Novo Nordisk Inc $1.83 07/18/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
695296353 Merck Sharp & Dohme Corporation $11.00 02/26/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
697771301 Teva Pharmaceuticals USA, Inc. $14.35 04/25/2019 Food and Beverage Undisputed 01/23/2026 View at CMS
704330813 Novo Nordisk Inc $32.27 04/04/2019 Education Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2019_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.